PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Black Diamond Therapeutics, Inc. (BDTX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS09203E1055
CUSIP09203E105
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$272.04M
EPS-$1.88
EBITDA (TTM)-$86.02M
Year Range$1.43 - $6.85
Target Price$12.80
Short %6.29%
Short Ratio3.76

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Black Diamond Therapeutics, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Black Diamond Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%NovemberDecember2024FebruaryMarchApril
-87.18%
54.45%
BDTX (Black Diamond Therapeutics, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Black Diamond Therapeutics, Inc. had a return of 80.07% year-to-date (YTD) and 230.72% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date80.07%6.33%
1 month-2.50%-2.81%
6 months164.92%21.13%
1 year230.72%24.56%
5 years (annualized)N/A11.55%
10 years (annualized)N/A10.55%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
202436.65%33.98%-1.46%
2023-14.84%-34.49%24.47%20.09%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current risk-adjusted rank of BDTX is 90, placing it in the top 10% of the market in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.

The Risk-Adjusted Performance Rank of BDTX is 9090
Black Diamond Therapeutics, Inc.(BDTX)
The Sharpe Ratio Rank of BDTX is 7777Sharpe Ratio Rank
The Sortino Ratio Rank of BDTX is 9898Sortino Ratio Rank
The Omega Ratio Rank of BDTX is 9696Omega Ratio Rank
The Calmar Ratio Rank of BDTX is 9494Calmar Ratio Rank
The Martin Ratio Rank of BDTX is 8383Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Black Diamond Therapeutics, Inc. (BDTX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


BDTX
Sharpe ratio
The chart of Sharpe ratio for BDTX, currently valued at 0.88, compared to the broader market-2.00-1.000.001.002.003.000.88
Sortino ratio
The chart of Sortino ratio for BDTX, currently valued at 4.88, compared to the broader market-4.00-2.000.002.004.006.004.88
Omega ratio
The chart of Omega ratio for BDTX, currently valued at 1.53, compared to the broader market0.501.001.501.53
Calmar ratio
The chart of Calmar ratio for BDTX, currently valued at 2.28, compared to the broader market0.002.004.006.002.28
Martin ratio
The chart of Martin ratio for BDTX, currently valued at 5.20, compared to the broader market0.0010.0020.0030.005.20
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.91, compared to the broader market-2.00-1.000.001.002.003.001.91
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.77, compared to the broader market-4.00-2.000.002.004.006.002.77
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.33, compared to the broader market0.501.001.501.33
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.46, compared to the broader market0.002.004.006.001.46
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.61, compared to the broader market0.0010.0020.0030.007.61

Sharpe Ratio

The current Black Diamond Therapeutics, Inc. Sharpe ratio is 0.88. A Sharpe ratio between 0 and 1.0 is considered sub-optimal.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.502.002.503.00NovemberDecember2024FebruaryMarchApril
0.88
1.91
BDTX (Black Diamond Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Black Diamond Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-88.71%
-3.48%
BDTX (Black Diamond Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Black Diamond Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Black Diamond Therapeutics, Inc. was 97.17%, occurring on Oct 13, 2022. The portfolio has not yet recovered.

The current Black Diamond Therapeutics, Inc. drawdown is 88.71%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-97.17%Jun 23, 2020583Oct 13, 2022
-53.95%Jan 31, 202033Mar 18, 202026Apr 24, 202059
-19.84%May 13, 202022Jun 12, 20206Jun 22, 202028
-17.8%Apr 28, 20204May 1, 20205May 8, 20209

Volatility

Volatility Chart

The current Black Diamond Therapeutics, Inc. volatility is 21.93%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%35.00%NovemberDecember2024FebruaryMarchApril
21.93%
3.59%
BDTX (Black Diamond Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Black Diamond Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items